PFIZER INC Long-term Investments and Receivables, Net
PFIZER INC (PFE) had Long-term Investments and Receivables, Net of $9.46 billion as of 2011-12-31, per its 10-K filed 2012-02-28.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:LongTermInvestmentsAndReceivablesNet · last filed 2012-02-28
- 2011-12-31: Long-term Investments and Receivables, Net $9.46B.
- 2011-10-02: Long-term Investments and Receivables, Net $9.47B.
- 2011-07-03: Long-term Investments and Receivables, Net $10.21B.
- 2011-04-03: Long-term Investments and Receivables, Net $9.81B.
| Period end | Long-term Investments and Receivables, Net | Long-term Investments and Receivables, Net as first filed |
|---|---|---|
| 2011-12-31 | $9.46B 10-K · filed 2012-02-28 | |
| 2011-10-02 | $9.47B 10-Q · filed 2011-11-10 | |
| 2011-07-03 | $10.21B 10-Q · filed 2011-08-11 | |
| 2011-04-03 | $9.81B 10-Q · filed 2011-05-12 | |
| 2010-12-31 | $9.75B 10-K · filed 2012-02-28 | $9.75B 10-K · filed 2011-02-28 |
| 2010-10-03 | $10.34B 10-Q · filed 2010-11-12 | |
| 2010-07-04 | $10.52B 10-Q · filed 2010-08-12 | |
| 2010-04-04 | $12.08B 10-Q · filed 2010-05-13 | |
| 2009-12-31 | $13.12B 10-K · filed 2011-02-28 | |
| 2009-09-27 | $12.17B 10-Q · filed 2009-11-05 | |
| 2009-06-28 | $12.58B 10-Q · filed 2009-08-06 | |
| 2008-12-31 | $11.48B 10-K · filed 2010-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |